Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013

What We Do Genomic Health is a global personalized genomics health company focusing on cancer Conduct studies to understand which patterns of gene expression within a tumor are linked to a response to cancer therapy or to the likelihood that the cancer will return or metastasize Develop clinically validated tests that provide the genomic profile of an individual’s tumor in the form of a “score” that helps individualize cancer treatment planning 2

Leading a Revolution in Cancer Care 3 * Estimated DCIS Breast Cancer Stage II/ MMR Colon Cancer Prostate Cancer Do I have an aggressive disease? Do I need surgery? surgery? Stage II/III Colon Cancer Do I need Do I needOxaliplatin? Invasive Breast Cancer Do I need Do I needchemotherapy? Do I need radiation? * 2014* NGS Research NGS Development

DCIS Breast Cancer Assay 4 “One of the year’s leading medical breakthroughs…” DCIS Score Identifies 75% of Patients with Lower Risk Disease Who May Avoid Radiation Treatment

Delivering Better Outcomes in Cancer Cancer’s Toll in million new cancers will be diagnosed in the U.S. 1 ~577,000 patients will die from their disease 1 80 billion dollars will be spent on cancer therapies with an average efficacy of 25% 2 60 billion dollars will be wasted In Early Stage ER+ Invasive Breast Cancer >100,000 patients will be diagnosed in the U.S. >50% percent will receive chemotherapy 3 <4% of N- patients will benefit from chemotherapy The Oncotype DX ® Value Proposition Demonstrated 37% change in early-stage breast cancer treatment decisions Hundreds of millions of dollars in healthcare savings >320,000 patients tested 5 1 ACS 2012; 2 Burrill 2009; 3 Company estimates

Thank You 6